-
Mashup Score: 1Viewpoint: New UK Data Show BA.2 Variant Produces More Frequent Hospitalizations Than Omicron - 2 year(s) ago
Evidence shows the BA.2 variant is more infectious and virulent than the Omicron variant.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 1Viewpoint: New UK Data Show BA.2 Variant Produces More Frequent Hospitalizations Than Omicron - 2 year(s) ago
Evidence shows the BA.2 variant is more infectious and virulent than the Omicron variant.
Source: Infection Control TodayCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2Hospitalizations of young children with the virus surged during the U.S. Omicron wave. - 2 year(s) ago
Health|Hospitalizations of young children with the virus surged during the U.S. Omicron wave.https://www.nytimes.com/2022/03/21/health/hospitalizations-of-young-children-with-the-virus-surged-during-the-us-omicron-wave.htmlCredit…Erin Schaff/The New York TimesBabies and children younger than age 5 were hospitalized with coronavirus at much higher rates during the latest U.S. surge, when the…
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Background: At the end of 2021, the B.1.1.529 SARS-CoV-2 variant (Omicron) wave superseded the B.1.617.2 variant (Delta) wave. Objective: To compare baseline characteristics and in-hospital outcomes of patients with SARS-CoV-2 infection with the Delta variant versus the Omicron variant in the emergency department (ED). Design: Retrospective chart reviews. Setting: 13 adult EDs in academic…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 39Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants - Nature Medicine - 2 year(s) ago
A test-negative case control analysis using data from a diverse population in California, USA, demonstrates that vaccine efficacy of a three-dose regimen of the mRNA-1273 COVID-19 vaccine is reduced against infection with the Omicron SARS-CoV-2 variant compared with Delta, but that efficacy against hospitalization remained high for both variants.
Source: NatureCategories: Latest Headlines, Oncologists1Tweet-
Lrg test-neg case-control study finds 3 doses of Moderna vaccine >99% protective vs hospitalization from #DeltaVariant or #Omicron. Vaccine protection vs infxn was lower, esp in #immunocompromised ppl (only 29% efficacy for them vs Omicron). #OncTwitter https://t.co/59PqH1Fq9F https://t.co/OXzXghoxjr
-
-
Mashup Score: 0
Background In countries with high COVID-19 vaccination rates the SARS-CoV-2 Delta variant resulted in rapidly increasing case numbers. This study evaluated the use of non-pharmaceutical interventions (NPIs) coupled with alternative vaccination strategies to determine feasible Delta mitigation strategies for Australia. We aimed to understand the potential effectiveness of high vaccine coverage…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
Background Evidence on vaccine-specific protection over time, in particular against the Delta variant, and protection afforded by a homologous third dose is urgently needed. Methods We used a previously published model and neutralization data for five vaccines—mRNA-1273, BNT162b2, NVX-CoV2373, V01, and CoronaVac— to evaluate long-term neutralizing antibody dynamics and predict time-varying…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 9The FDA limits the use of some monoclonal antibodies treatments - 2 year(s) ago
The Food and Drug Administration is curbing the use of two out of three monoclonal antibody treatments because new data shows they aren’t effective against the omicron variant.
Source: NPR.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 95Effectiveness of a Third Dose of mRNA Vaccines ... - 2 year(s) ago
This report describes COVID-19 vaccine effectiveness time frames among people who received their first and second doses of the vaccine series, and effectiveness of third vaccine doses during both Delta- and Omicron-predominant periods.
Categories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis - 2 year(s) ago
Humoral and cellular immune responses after standard two-dose COVID-19 vaccination are reduced in immunosuppressed patients with antineutrophil cytoplasmic antibodies associated vasculitis (AAV).1–3 Emerging variants such as B.1.617.2 (delta) are of particular concern because of their higher transmissibility and partial immune escape.4 AAV patients with lower neutralising antibody levels may…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
Effect of a third dose in ANCA-associated #vasculitis? ▶️ patients may not be protected against #deltavariant with a standard 2-doses regimen ▶️ a third dose induced a strong antibody activity against delta in most patients, but not in those w/rituximab 🔗 https://t.co/suaRhH0Nf0 https://t.co/5q1xLj8xrw
-
The BA.3 variant is more infectious and virulent than the Omicron variant evidence shows. https://t.co/f4vWq6wQcT #ba.3variant #omicron #england #deltavariant #nhs https://t.co/OLLub8HENV